EC expected to dish out more pay-for-delay fines

Home/Policies & Legislation | Posted 01/08/2014 post-comment0 Post your comment

The European Commission (EC) is planning to fine French drugmaker Les Laboratoires Servier (Servier) and generics giant Teva Pharmaceutical Industries (Teva) in its latest round of investigations over so-called ‘pay-for-delay’ deals.

Pay for Delay V13C29

The fines are to be imposed on Servier and Teva, as well as up to four other generics companies, due to what the EC terms ‘anticompetitive agreements’ which the companies entered into and which the EC finds delayed the entry of generics on to the market.

The drug in question here is Servier’s hypertension treatment, Aceon (perindopril). The drug is an angiotensin converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension) and to prevent heart attack in people with coronary artery disease.

This is not the first time the EC has imposed fines on companies for what it terms ‘anticompetitive agreements’. Denmark’s Lundbeck and four generics companies were fined Euros 146 million in June 2013 for similar pay-for-delay deals, related to Lundbeck’s antidepressant Celexa (citalopram) [1].

Six months later, Johnson & Johnson and Novartis were fined Euros 16.3 million for anticompetitive agreements, which the EC believes delayed the market entry of a generic version of the painkiller Duragesic (fentanyl) in The Netherlands [2].

The fines for Servier and Teva are expected to be announced by the end of July 2014.

Related articles
Lundbeck fights back against EU pay-for-delay fine

EC accuses J&J and Novartis of delaying generic fentanyl

References
1. GaBI Online - Generics and Biosimilars Initiative. Lundbeck and 4 generics makers fined for pay-to-delay deals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Policies-Legislation/Lundbeck-and-4-generics-makers-fined-for-pay-for-delay-deals
2. GaBI Online - Generics and Biosimilars Initiative. EU problematic patent settlements remain at low level [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Reports/EU-problematic-patent-settlements-remain-at-low-level

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: Bloomberg, Reuters

comment icon Comments (0)
Post your comment
Related content
Public consultation for the modification of the biosimilars regulation
02 AA010638
Home/Policies & Legislation Posted 16/01/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
ANVISA's decision on 'Skinny labels' for generics pending
Labelling V14I26
Home/Policies & Legislation Posted 14/11/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010